CN106822877A - A kind of composition for treating HPV infection and its application - Google Patents
A kind of composition for treating HPV infection and its application Download PDFInfo
- Publication number
- CN106822877A CN106822877A CN201611259548.3A CN201611259548A CN106822877A CN 106822877 A CN106822877 A CN 106822877A CN 201611259548 A CN201611259548 A CN 201611259548A CN 106822877 A CN106822877 A CN 106822877A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- hpv infection
- mussel
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000009608 Papillomavirus Infections Diseases 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 58
- 235000020638 mussel Nutrition 0.000 claims abstract description 56
- 210000004872 soft tissue Anatomy 0.000 claims abstract description 44
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 29
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 29
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000005642 Oleic acid Substances 0.000 claims abstract description 29
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 29
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 29
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 26
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 26
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims description 22
- 239000003921 oil Substances 0.000 claims description 21
- 235000019198 oils Nutrition 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 6
- -1 flavouring Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 240000008886 Ceratonia siliqua Species 0.000 claims description 3
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 3
- 241001147138 Mytilus galloprovincialis Species 0.000 claims description 3
- 241001245601 Perna viridis Species 0.000 claims description 3
- 239000000975 dye Substances 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 241000727169 Prinsepia utilis Species 0.000 claims description 2
- 239000003070 absorption delaying agent Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 235000007215 black sesame Nutrition 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007951 isotonicity adjuster Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000011149 active material Substances 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000010475 evening primrose oil Substances 0.000 claims 1
- 229940089020 evening primrose oil Drugs 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 235000019605 sweet taste sensations Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 7
- 206010059313 Anogenital warts Diseases 0.000 abstract description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 abstract description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 4
- 201000010881 cervical cancer Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 18
- 201000010153 skin papilloma Diseases 0.000 description 12
- 208000000260 Warts Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010027252 Trypsinogen Proteins 0.000 description 1
- 102000018690 Trypsinogen Human genes 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21004—Trypsin (3.4.21.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to medical field, more particularly to a kind of composition for treating HPV infection and its application.Said composition includes mussel soft tissue extract, trypsase and oleic acid and/or linoleic acid and/or the oil rich in them.Composition of the invention can be used for treating HPV infection and the relevant disease of HPV infection, such as cervix cancer and genital wart disease, for HPV infection patient provide good effect, onset time it is short, without the HPV infection medication for relying on, having no toxic side effect, recurrence rate is low.
Description
Technical field
The invention belongs to field of medicaments, more particularly to a kind of composition for treating HPV infection and its application.
Background technology
HPV (Human papillomavirus, HPV) belongs to the Papillomavirus of Papillomaviridae,
It is spherical nonencapsulated small-sized double-stranded circular DNA virus.Have now been found that its have more than 200 kind, according to its it is whether carcinogenic can be by HPV
It is divided into high-risk-type and low risk.Current 15 kinds of high-risk HPVs of more unified epidemiology class definition (such as HPV-16, HPV-
18) with 12 kinds of low risk HPV (such as HPV-6, HPV-11).The mechanism of causing a disease of HPV is that HPV has height to skin and mucosal epithelial cells
The close preferendum of degree, it, can the self-replacation or to be incorporated into host thin in nucleus after infection host skin or mucosal epithelial cells
In born of the same parents DNA, and synchronously replicate and transcribe with host cell.Virus replication induces epitheliosis, makes epidermis thickening with hyperacanthosis
Keratinization of epidermis, ultimately results in epitheliosis and forms papilloma, also known as wart to a certain degree.Wart is usually benign, and its
Middle HPV DNA are free.But the HPV of some types has the ability of inducing cell transformation, its DNA can be incorporated into host epithelial
In the chromosome of cell, promote the synthesis of cell DNA, skin particularly mucosal epithelial cells is changed into immortalized cells, so that
Induce precancerous lesion or malignant tumour.
HPV infection can cause various lesions, and its clinical manifestation is also varied.Pregnant woman and the population infection of hypoimmunity
The state of an illness will be even more serious afterwards.It is common to have following several：Cervicitis, cervical erosion, cutaneous papilloma, genital wart, flat wart
Deng even resulting in malignant tumour.
Current HPV it is positive mainly beyond control based on, inside control supplemented by.The outer method controlled is a lot, including drug therapy, freezing
Treatment, laser therapy, micro-wave therapeutic, electricity burn treatment and operative treatment etc..Drug therapy is convenient, it is easy to operate, but some medicines
There is the possibility of mucous membrane of burning.Injecting the immunopotentiators such as expensive interferon, interleukin can play a role, but its curative effect exists
Academia remains dispute, and most people can produce certain side effect.
Mussel (Mytilusedulis Linnaeus) is a kind of sea mollusk, belongs to bivalve shellfish, is commonly called as " blue or green
Mouthful " and " mussel ", each coastwise contries of throughout world.Mussel species are various, and only coastal area of china just has kind more than 30, and economic worth is higher
Have kind more than 10, wherein Mytilus galloprovincialis, Perna viridis and Trachyostracous mussel is main breed variety.Enriched Mussel containing protein, fat,
The nutrients such as carbohydrate, calcium, phosphorus, iron, riboflavin, niacin, and with medical value very high.
Trypsase (Trypsin, Parenzyme), EC 3.4.21.4 are the one kind extracted from the pancreas of ox, sheep, pig
Serine protein hydrolase.After the precursor trypsinogen of pancreas manufacture is secreted into small intestine, erepsin activates it, as pancreas egg
White enzyme.Trypsase is endopeptidase, the carboxyl that it can optionally in the lysine and arginine residues of hydrolyzed peptide chain.
Trypsase not only plays digestive ferment, and can also limit decomposition chymotrypsinogen, procarboxypeptidase, phosphatide proenzyme etc. other
The precursor of enzyme, plays activation.
Oleic acid (Oleic acid) is a kind of single unsaturation Omega-9 aliphatic acid, and linoleic acid (Linoleic acid) is one
Unsaturation Omega-6 aliphatic acid is planted, they are all required aliphatic acid in humans and animals nutrition.
The content of the invention
To solve, HPV treatment methods inconvenient operations, side effect be big, expensive defect, and the present invention especially proposes one
The composition for treating HPV infection is planted, can be used for treating HPV infection and the relevant disease of HPV infection, such as cervix cancer and life
Grow the diseases such as device wart, for HPV infection patient provide good effect, onset time it is short, without relying on, have no toxic side effect, recurrence rate it is low
HPV infection medication.
To achieve the above object, the present invention proposes a kind of composition for treating HPV infection, it is characterised in that the treatment
The composition of HPV infection is by mussel soft tissue extract, trypsase and oleic acid and/or linoleic acid and/or rich in them
Oil composition, or be mainly made up of them.
One or more aspects of the invention, the composition of the treatment HPV infection is wrapped based on composition levels
Include：0.1-15 parts, trypsase 0.1-20 parts of mussel soft tissue extract and oleic acid and/or linoleic acid and/or rich in them
Oily 0.1-10 parts.
One or more implementation methods of the invention, based on composition total weight, mussel soft tissue extract is example
As 0.1 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5
Part, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts,
14.5 parts, 15 parts etc., trypsase is such as 0.1 part, 0.2 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5
Part, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts,
12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts,
18.5 parts, 19 parts, 19.5 parts, 20 parts etc., and oleic acid and/or linoleic acid and/or the oil rich in them be such as 0.1 part, 1
Part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5
Part, 9 parts, 9.5 parts, 10 parts etc..
One or more aspects of the invention, the composition of the treatment HPV infection：Mussel soft tissue extract with
Trypsase can be individually insulated presence or can be mixed.Here, " isolation is present " refers to two kinds of compositions to keep respective
The non-interfering independent packaging of property is present." being mixed " refers to that two kinds of compositions are mixed in a packaging.According to
In one or more aspects of the invention, the composition for treating HPV infection：Mussel soft tissue extract and tryptose
Enzyme can be premixed or use preceding mixing.
One or more aspects of the invention, include but is not limited to following living rich in oleic acid and/or linoleic oil
One or more in property material：Locust bean oil, safflower oil, black sesame oil, prinsepia utilis royle oil, grape-kernel oil, olive oil, oenothera biennis
Oil, tea-seed oil.Specifically, it can be 0.1-5 parts.
One or more aspects of the invention, the composition of the treatment HPV infection can further add auxiliary material,
The auxiliary material can be antioxidant, bacteriostatic agent, essence or host material etc..
One or more aspects of the invention, the final ph of the composition of the treatment HPV infection can be with 3.8-
5.8, for example, 3.8-5.5, such as be 4.0-5.6.
One or more aspects of the invention, in the composition of the treatment HPV infection：Mussel soft tissue extract
Can be dry powder with trypsase.
One or more aspects of the invention, in the composition of the treatment HPV infection：Mussel soft tissue is extracted
Thing, trypsase can be liquid.
One or more aspects of the invention, the mussel soft tissue extract is all in addition to shell with mussel
Component is raw material, and the supernatant for being extracted by acidic aqueous solution and being obtained, wherein protein content are 0.2-15.0mg/ml, pH
Value 1.0-6.0, for example, 2.0-5.0, for example, 3.0-4.0, for example, 4.5-5.5.Especially, can be with byssus as former
Material.
One or more aspects of the invention, the mussel can include Mytilus galloprovincialis, Perna viridis and Trachyostracous mussel
In one kind, two or three.
One or more implementation methods of the invention, the acidic aqueous solution can include：Acetic acid-acetate buffer
Liquid, acetic acid, citric acid, perchloric acid etc., but not limited to this.
One or more implementation methods of the invention, the protein content of the mussel soft tissue extract can be
Such as 0.2mg/ml, 0.3mg/ml, 0.4mg/ml, 0.5mg/ml, 0.6mg/ml, 0.7mg/ml, 0.8mg/ml, 0.9mg/ml,
1.0mg/ml、1.5mg/ml、2.0mg/ml、2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、
5.0mg/ml、5.5mg/ml、6.0mg/ml、6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、
9.0mg/ml、9.5mg/ml、10.0mg/ml、10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/
Ml, 13.0mg/ml, 13.5mg/ml, 14.0mg/ml, 14.5mg/ml and 15.0mg/ml etc., but not limited to this.
One or more aspects of the invention, the trypsase can be conventional purchase from the market.Substitute
Ground, the trypsase can be by saltouing, it is prepared by the method such as column chromatography.
One or more aspects of the invention, the oleic acid and/or linoleic acid and/or the oil rich in them can be
Routine is bought from the market.
One or more aspects of the invention, it is described to can be used for treating HPV for treating the composition of HPV infection
Infection, control microorganism infection, elimination redness, pain of alleviation.
Additionally, the present invention also proposes a kind of medicine for treating HPV infection, including mussel soft tissue extract, trypsase
And oleic acid and/or linoleic acid and/or the oil rich in them, optionally, can also be conventional or acceptable containing other field of medicaments
Auxiliary material.
One or more aspects of the invention, the medicine of the treatment HPV infection can be prepared into spray, drops,
The forms such as gel, ointment, effervescent tablet, oral solution, granule.
Additionally, the invention allows for above-mentioned treatment HPV infection medicine treat HPV infection in application.
One or more aspects of the invention, the medicine of the treatment HPV infection can be used for treating HPV infection
(including high-risk-type and low risk, especially high-risk-type) and the relevant disease of HPV infection, such as cervix cancer and genital wart
Disease.
One or more aspects of the invention, composition of the invention, institute are given to subject in need
Stating composition includes mussel soft tissue extract, trypsase and oleic acid and/or linoleic acid and/or the oil rich in them.
One or more implementation methods of the invention, the mussel soft tissue extract, trypsase and oleic acid
And/or linoleic acid and/or the oil rich in them are mixed in composition.
One or more implementation methods of the invention, the mussel soft tissue extract, trypsase and oleic acid
And/or linoleic acid and/or the oil rich in them can also be individually insulated to be present in composition.Here, when by soft group of mussel
When knitting extract, trypsase and oleic acid and/or linoleic acid and/or the oily combination medicine-feeding rich in them, administration can be suitable
Sequence is administered or is administered simultaneously, and preferably can be order of administration.For order of administration, mussel soft tissue can be extracted
Thing, trypsase and oleic acid and/or linoleic acid and/or the oil rich in them are administered in any order.For example, can first give
Mussel soft tissue extract gives trypsase and then gives oleic acid and/or linoleic acid and/or the oil rich in them, Huo Zheke again
Mussel soft tissue extract is given again first giving trypsase gives oleic acid and/or linoleic acid and/or oil rich in them again,
In whole treatment cycle, the administration frequency of three can be with identical or different.
In one aspect of the invention, a kind of composition for treating HPV infection, including：
0.1-15 parts of mussel soft tissue extract,
Trypsase 0.1-20 parts, and
Oleic acid 0.1-10 parts.
In one aspect of the invention, a kind of composition for treating HPV infection, including：
0.1-15 parts of mussel soft tissue extract,
Trypsase 0.1-20 parts, and
Linoleic acid 0.1-10 parts.
In one aspect of the invention, a kind of composition for treating HPV infection, including：
0.1-15 parts of mussel soft tissue extract,
Trypsase 0.1-20 parts,
Linoleic acid 0.1-10 parts, and
0.1-5 parts of locust bean oil.
Additionally, the present invention also proposes a kind of pharmaceutical composition for treating HPV infection, contain mussel soft tissue extract, pancreas
Protease and oleic acid and/or linoleic acid and/or the oil rich in them, optionally, can also pharmaceutically commonly use or can connect containing other
The carrier received.
One or more aspects of the invention, the carrier can include any and all of solvent, solubilizer,
Salt, decentralized medium, coating material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent,
Absorption delaying agent, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and they
Middle a kind of, various or whole combination, this is well-known to those skilled in the art (for example, see Remington's
Pharmaceutical Sciences,18th Ed.Mack Printing Company,1990,pp.1289-1329).Except
Outside the carrier incompatible with active component, it is contemplated that any conventional carrier used in treatment use or pharmaceutical composition.
Using comprising mussel soft tissue extract, trypsase and oleic acid and/or linoleic acid and/or oily rich in them
Treat HPV infection composition can be used for treatment HPV infection (including high-risk-type and low risk, especially high-risk-type) and
The relevant disease of HPV infection, such as cervix cancer and genital wart disease.
Good effect, onset time be short, nothing for HPV infection patient provides for the composition for the treatment of HPV infection of the present invention
Rely on, have no toxic side effect, the HPV infection articles for use that recurrence rate is low.
Following examples are illustrated by taking the composition for treating HPV infection as an example, but not limited to this, and the invention described above is proposed
Various oily preventions comprising mussel soft tissue extract, trypsase and oleic acid and/or linoleic acid and/or rich in them and
Treatment HPV infection composition is applied to the present invention.
Specific embodiment
Embodiment 1：A kind of preparation method of mussel soft tissue extract.
Take mussel to shell, collect soft tissue 300g, be divided into three parts, every part adds the following table acidity of 100ml contents 0.3% molten
Liquid, centrifugation obtains supernatant as mussel soft tissue extract after homogenate 10min.
Protein content and pH value in supernatant are determined, determining the protein quantity uses Coomassie Brilliant Blue.
Table 1
| Example | Acid solution | Protein content | PH value |
| 1 | Citric acid | 2.6mg/ml | 4.5 |
| 2 | Acetic acid | 3.5mg/ml | 3.2 |
| 3 | Perchloric acid | 3.0mg/ml | 1.0 |
Embodiment 2：A kind of composition comprising mussel soft tissue extract, trypsase and oleic acid
The composition of the treatment HPV infection comprising mussel soft tissue extract, trypsase and oleic acid is by following components structure
Into：Mussel soft tissue extract dry powder 15mg, trypsase dry powder 20mg, oleic acid 10ml add purified water to be obtained after fully dissolving
Treat the oral solution of HPV infection.
Collect HPV infection patient, without clinical symptoms, through HPV DNA typings detection infection high-risk HPV virus (including
16th, 18,31,33,35,39,45,51 types etc.) female patient 30, be randomly divided into test group and control group.Test group is taken
The composition for the treatment of HPV infection prepared by embodiment 2, one time a day, a 15ml, is spaced 24h medications, prohibitive during medication
Life and bath in a tub, menstrual period pause are continuous to use 2 weeks.Control group does not use any remedy measures.After the treatment of all patients extremely
Sexual life whole process in the check phase uses sheath.Two groups of patients carry out HPV detections with after being discontinued 1 month before the treatment.
Result shows that the patient's HPV viruse carrying capacity for having 86.67% using test group after the present invention is detected less than 1.00RLU/
Co (HC2 methods), and control group only has 20%.Patient's HPV viruse carrying capacity of test group averagely have dropped 89.26%, and control group
HPV viruse carrying capacity averagely increase 4.89% on the contrary.Show that composition of the invention has the effect for the treatment of HPV infection.
Embodiment 3：One kind includes mussel soft tissue extract, trypsase and linoleic composition
Composition comprising mussel soft tissue extract, trypsase and linoleic treatment HPV infection is by following components
Constitute：Mussel soft tissue extract dry powder 10mg, trypsase dry powder 15mg, linoleic acid 5ml, mussel soft tissue extract and pancreas
Protease is sieved, and amylum pregelatinisatum, microcrystalline cellulose, sodium carboxymethylcellulose are mixed, and the Hydroxypropyl methylcellulose with 5% is water-soluble
Liquid granulation, 60 DEG C of drying, the low-substituted hydroxypropyl cellulose of recipe quantity, superfine silica gel powder, trypsase, mussel soft tissue are extracted
Mix with particle after thing, linoleic acid are well mixed, granule is made after packing.
Collect 30 cervical HPV infection patients, the age between 20-50, course of disease 3-21 months.Cervical HPV infection is diagnosed
Standard is：Cervical exfoliated cell is taken, RLU/Co >=1.0 of sample are detected, cervical HPV infection is diagnosed as positive.Drug dosage is
Take the granule of the treatment HPV infection of the preparation of embodiment 3, daily 1 time, a 10g.Continuous use treats 2 Zhou Houfu
Look into.
Criterion of therapeutical effect：Continuous use checks HPV-DNA after 2 weeks, fully recovered during RLU/Co ＜ 1.0；During RLU/Co ＜ 10.0
It is as effective；It is as invalid during RLU/Co ＞ 10.0.
Clinical effectiveness：In 30 patients, fully recover 25, cure rate 83.33%, effective 3, efficient (containing recovery from illness)
93.33%, invalid 2, inefficiency is 6.67%.
Conclusion：The composition of present invention treatment HPV infection has good therapeutic action to the patient of HPV infection.
Embodiment 4：A kind of composition comprising mussel soft tissue extract, trypsase and oleic acid
The composition of the treatment HPV infection comprising mussel soft tissue extract, trypsase and oleic acid is by following components structure
Into：Mussel soft tissue extract dry powder 8.5mg, trypsase dry powder 10.5mg, oleic acid 6ml, add physiological saline fully to dissolve
It is made spray.
HPV infection flat wart patient 30 is collected, test group and control group, every group 15 groups is randomly divided into.Test group is used
Spray prepared by the present embodiment 4, control group is using separately taking mussel soft tissue extract dry powder 8.5mg, trypsase dry powder
10.5mg, adds physiological saline fully to dissolve the spray of preparation.Two groups of application methods are identical, and 3 times a day, and affected part 3- is sprayed on every time
Under 5,2 weeks is a course for the treatment of, and curative effect is observed after a course for the treatment of.
Criterion of therapeutical effect：Recovery from illness-wart body comes off, skin smooth；Effective-wart body is obviously reduced or thinning is more than 50%；Wart body
It is obviously reduced or thinning is less than 50%；Invalid-course for the treatment of terminates wart body without being obviously reduced or thinning.Viewing test group after one course for the treatment of
With control group curative effect, therapeutic effect is as shown in table 2 below：
| Group | Recovery from illness | It is effective | Effectively | It is invalid | It is efficient |
| Test group | 12 | 1 | 1 | 1 | 93.33% |
| Control group | 10 | 2 | 1 | 2 | 86.67% |
From upper table data can be seen that the spray that test group and control group use have to HPV infection flat wart it is significant
Curative effect, and the embodiment of the present invention 4 prepare the spray containing mussel soft tissue extract, trypsase and oleic acid effective percentage
Apparently higher than control group, and then prove that the present invention adds the spray prepared after oleic acid and/or linoleic acid and/or the oil rich in them
Therapeutic effect to HPV infection flat wart is more preferable.
Certainly, the present invention can also have other various embodiments, ripe in the case of without departing substantially from spirit of the invention and its essence
Knowing those skilled in the art can make various corresponding changes and deformation, but these corresponding changes and deformation according to the present invention
The protection domain of the claims in the present invention should all be belonged to.
Claims (10)
1. a kind of composition for treating HPV infection, it is characterised in that the composition of the treatment HPV infection includes soft group of mussel
Knit extract, trypsase and oleic acid and/or linoleic acid and/or the oil rich in them.
2. the composition of the treatment HPV infection according to any preceding claims, it is characterised in that treatment HPV sense
The composition of dye based on composition total weight, 0.1-15 parts, trypsase 0.1-20 parts of mussel soft tissue extract and oleic acid
And/or linoleic acid and/or oily 0.1-10 parts rich in them, such as based on composition total weight, mussel soft tissue extract is
Such as 0.1 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5
Part, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts, 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts,
14.5 parts, 15 parts, trypsase is such as 0.1 part, 0.2 part, 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5
Part, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, 10.5 parts, 11 parts, 11.5 parts,
12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts,
18.5 parts, 19 parts, 19.5 parts, 20 parts, and oleic acid and/or linoleic acid and/or the oil rich in them be such as 0.1 part, 1 part,
1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9
Part, 9.5 parts, 10 parts.
3. according to any preceding claims treatment HPV infection composition, it is characterised in that the composition also contains
There is one or more in following active material：Locust bean oil, safflower oil, black sesame oil, prinsepia utilis royle oil, grape-kernel oil, olive oil,
Evening primrose oil, tea-seed oil.
4. according to any preceding claims treatment HPV infection composition, it is characterised in that the composition enters one
Step includes auxiliary material, such as antioxidant, bacteriostatic agent, essence or host material；Or the composition is further included pharmaceutically
Acceptable carrier, solvent, salt, decentralized medium, coating material, surfactant, antioxidant, preservative such as are (for example
Antiseptic, antifungal agent), it is isotonic agent, absorption delaying agent, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweet
Taste agent, flavouring, dyestuff and combination a kind of, various or whole in them.
5. according to any preceding claims treatment HPV infection composition, it is characterised in that the composition is dissolved in
Final ph in water is 3.8-5.8.
6. according to any preceding claims treatment HPV infection composition, it is characterised in that the mussel soft tissue
Extract, trypsase are dry powder or liquid.
7. according to any preceding claims treatment HPV infection composition, it is characterised in that the mussel soft tissue
Extract is the component raw material in addition to shell with mussel, is extracted by acidic aqueous solution, and supernatant acquisition is taken after centrifugation, wherein
Protein content 0.2-15.0mg/ml, pH value 1.0-6.0.
8. it is according to claim 7 treatment HPV infection composition, wherein the acidic aqueous solution includes：Acetic acid-acetic acid
Sodium buffer solution, acetic acid, citric acid, perchloric acid, or the protein content of wherein described mussel soft tissue extract is, for example,
0.2mg/ml、0.3mg/ml、0.4mg/ml、0.5mg/ml、0.6mg/ml、0.7mg/ml、0.8mg/ml、0.9mg/ml、
1.0mg/ml、1.5mg/ml、2.0mg/ml、2.5mg/ml、3.0mg/ml、3.5mg/ml、4.0mg/ml、4.5mg/ml、
5.0mg/ml、5.5mg/ml、6.0mg/ml、6.5mg/ml、7.0mg/ml、7.5mg/ml、8.0mg/ml、8.5mg/ml、
9.0mg/ml、9.5mg/ml、10.0mg/ml、10.5mg/ml、11.0mg/ml、11.5mg/ml、12.0mg/ml、12.5mg/
Ml, 13.0mg/ml, 13.5mg/ml, 14.0mg/ml, 14.5mg/ml and 15.0mg/ml.
9. it is according to claim 7 treatment HPV infection composition, wherein the mussel include Mytilus galloprovincialis, Perna viridis,
One kind in Trachyostracous mussel, two or three.
10. the composition of the treatment HPV infection according to any preceding claims, it is characterised in that the composition is
Spray, drops, gel, ointment, effervescent tablet, oral solution, the form of granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611259548.3A CN106822877A (en) | 2016-12-30 | 2016-12-30 | A kind of composition for treating HPV infection and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611259548.3A CN106822877A (en) | 2016-12-30 | 2016-12-30 | A kind of composition for treating HPV infection and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822877A true CN106822877A (en) | 2017-06-13 |
Family
ID=59114942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611259548.3A Withdrawn CN106822877A (en) | 2016-12-30 | 2016-12-30 | A kind of composition for treating HPV infection and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822877A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | Antiviral use of mussel adhesive proteins |
-
2016
- 2016-12-30 CN CN201611259548.3A patent/CN106822877A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011286A1 (en) * | 2017-07-14 | 2019-01-17 | Jiangyin Usun Pharmaceutical Co., Ltd. | Antiviral use of mussel adhesive proteins |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885857B (en) | Extraction method of periplaneta americana extract for treating peptic ulcer | |
| KR20180033517A (en) | Mussel adhesive protein product, and its use for inhibiting mucosal inflammation | |
| CN101292969B (en) | Application of butyric acid (butanoic acid) in preparing medicaments for treating anorectal diseases | |
| WO2002072123A1 (en) | Preventives or remedies for tumor or papillomaviral diseases | |
| WO2004060381A1 (en) | Rabbit skin comprising biological active substance and its use | |
| CN108743621A (en) | The bear gall powder and preparation method of ice crystal state | |
| CN102743739B (en) | Preparation method for blattodea polypeptide substance, and medical use of blattodea polypeptide substance in anti-herpesvirus | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN106822877A (en) | A kind of composition for treating HPV infection and its application | |
| CN104324125A (en) | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof | |
| CA2619157A1 (en) | Anti-human papillomas virus composition | |
| CN106798916A (en) | A kind of composition for treating HPV infection and its application | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN109700832A (en) | Pharmaceutical composition comprising bacillus licheniformis and American-cockroach-extract | |
| CN100364512C (en) | Houjiling prepn for treating throat diseases and its use | |
| CN108619486B (en) | Ointment for treating skin diseases and preparation method thereof | |
| CN106822879A (en) | A kind of composition for treating herpes simplex virus and its application | |
| CN113080450A (en) | Health food for inhibiting and killing helicobacter pylori and preparation method thereof | |
| CN107007826B (en) | Active protein of isatis root and its preparing process and application | |
| CN104510809A (en) | Antiviral new application of radix sanguisorbae or extract thereof | |
| CN109248244A (en) | A kind of Chinese medicine and preparation method thereof for treating gynaecological imflammation | |
| CN106977583A (en) | A kind of oligopeptides and preparation method and application | |
| CN106581663A (en) | Composition for treating hormone-dependent dermatitis | |
| CN100589841C (en) | A kind of traditional Chinese medicine paste for treating oral diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170613 |
|
| WW01 | Invention patent application withdrawn after publication |